Loading
Lynn Schuchter is Chief of Hematology-Oncology at the University of Pennsylvania, within the Abramson Cancer Center, and served as President of the American Society of Clinical Oncology (ASCO) for 2023 to 2024. A medical oncologist specialising in melanoma and immunotherapy, her work includes adjuvant immunotherapy and targeted therapy trials. Her papers include a Journal of Clinical Oncology editorial weighing the dose of adjuvant interferon therapy for melanoma and an Annals of Internal Medicine prognostic model for patients with primary melanoma from the Pigmented Lesion Group. She combines melanoma clinical research with professional leadership.
| Title | Journal | Year |
|---|---|---|
| Adjuvant Interferon Therapy for Melanoma: High-Dose, Low-Dose, No Dose, Which Dose? | Journal of Clinical Oncology | 2004 |
| A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group | Annals of Internal Medicine | 1996 |
Shares Abramson Cancer Center, University of Pennsylvania, Melanoma.
Shares American Society of Clinical Oncology (ASCO), Melanoma.
Shares American Society of Clinical Oncology (ASCO), Melanoma.
Shares Abramson Cancer Center, University of Pennsylvania, Melanoma.